Wells Fargo & Company Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its target price cut by equities researchers at Wells Fargo & Company from $28.00 to $26.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of 134.66% from the company’s current price.

A number of other research analysts have also recently issued reports on KROS. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Truist Financial dropped their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. William Blair cut shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Finally, Piper Sandler lowered their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Trading Up 0.6 %

NASDAQ KROS opened at $11.08 on Thursday. The firm’s 50 day simple moving average is $12.52 and its 200 day simple moving average is $39.56. The firm has a market capitalization of $448.82 million, a price-to-earnings ratio of -2.13 and a beta of 1.39. Keros Therapeutics has a 1 year low of $9.77 and a 1 year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. On average, equities research analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after buying an additional 46,041 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Keros Therapeutics by 14.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after acquiring an additional 32,492 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Keros Therapeutics in the fourth quarter worth approximately $388,000. Barclays PLC boosted its holdings in Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after acquiring an additional 35,022 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Keros Therapeutics during the 3rd quarter valued at approximately $603,000. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.